CurrentBlue Cross Blue Shield - Rhode IslandPolicy N/A

Focal Treatments for Prostate Cancer

Defines coverage stance for focal ablation therapies (eg, focal laser, HIFU, cryoablation, RFA, photodynamic therapy, irreversible electroporation, magnetic nanoparticle ablation) for localized prostate cancer for Medicare Advantage and Commercial products of Blue Cross Blue Shield - Rhode Island.

Policy Summary

PayerBlue Cross Blue Shield - Rhode Island

PolicyFocal Treatments for Prostate Cancer

Policy CodePolicy N/A

Change TypeMinor — no material changes

Effective Date06|01|2026

Next Review DateN/A

Key ActionVerify member-specific benefits and eligibility with the applicable benefit booklet or provider call center before providing focal therapy services.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

313,780estimated new US prostate cancer cases in 2025

35,770estimated US prostate cancer deaths in 2025

~61number of references cited

2010-2023FDA timeline mentioned

Coverage Criteria for Focal Prostate Therapies

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medicare Advantage Coverage

Medicare Advantage stance: Use of any focal therapy modality to treat patients with localized prostate cancer is not covered as the evidence is insufficient to determine the effects of the technology on health outcomes.

applies to Medicare Advantage Plans

Commercial Coverage

Commercial Products stance: Use of any focal therapy modality to treat patients with localized prostate cancer is not medically necessary as the evidence is insufficient to determine the effects of the technology on health outcomes.

applies to Commercial Products

This evidence review does not cover focal brachytherapy.

If services are determined to be not medically necessary or are non-covered benefits, providers may not charge the member for those services unless the member has been informed in advance and has signed a written agreement to accept financial responsibility to continue treatment at their own expense; member benefits and eligibility are governed by the subscriber agreement, member certificate, or employer agreement and providers should contact the provider call center for member-specific information.

For Commercial Products, use of any focal therapy modality to treat patients with localized prostate cancer is considered not medically necessary because the evidence is insufficient to determine the effects of these technologies on health outcomes. Specific CPT codes listed in the policy (for example, 0655T, 0739T, and 55880) are identified as not covered or not medically necessary as indicated, and the unlisted code 55899 is provided when no assigned CPT exists.

When services are determined to be not medically necessary or are non-covered benefits, those instances are subject to the member’s benefit and eligibility rules in the subscriber agreement or employer agreement. Providers must verify member-specific coverage before providing care and, except where the member has provided a signed, informed written agreement accepting financial responsibility, such services may not be billed to the member.

Coding and Billing

Not covered / Not medically necessary codesCPTNot Covered

0655T	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging
0739T	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation
55880	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance

Unlisted procedure code to be used when no CPT assignedCPT

55899

Unlisted procedure, male genital system

Provider Actions and Billing Guidance

Prior Authorization

Prior authorization: Not applicable at a policy level, but requirements may vary by contract. Providers must verify prior authorization requirements for the member's specific plan before scheduling services.

Check member-specific benefit booklet or evidence of coverage for prior authorization rules

Note

Verify Member Coverage

Benefits and eligibility vary by contract. Providers must verify member-specific coverage and benefits before providing services.

Contact the provider call center to confirm member benefits and eligibility

Note

Contract-Level Benefit Verification

Providers should consult the applicable benefit booklet, evidence of coverage, or subscriber agreement to determine whether services are covered under the member's contract.

Reference member’s contract documents for coverage determinations

Denial Risk

Denial Risk for Focal Therapies

For Medicare Advantage members, focal therapy modalities to treat localized prostate cancer are not covered; for Commercial members, these modalities are considered not medically necessary. Claims for the listed CPT codes and unlisted code 55899 are subject to denial.

Not covered / Not medically necessary codes: 0655T, 0739T, 55880, 55899

Billing Rule

Member Financial Liability for Non-covered Services

If a service is determined to be not medically necessary or is a non-covered benefit under the member’s contract, the provider may not bill the member unless the member was informed in advance and provided written agreement to accept financial responsibility.

Obtain written informed consent from the member before performing non-covered services if the member will be financially liable
Do not balance-bill members for services determined not medically necessary unless written agreement is obtained in advance

Documentation Required

Documentation and Submission Guidance

Provider action: document medical necessity thoroughly in the medical record and include supporting imaging, pathology, and consult notes when submitting claims for novel or focal procedures.

Include imaging and pathology reports with claim submission
Attach consult notes that justify the procedure and prior treatment attempts

Background and Scope

Focal treatment aims to ablate identified prostate cancer lesions (commonly the index lesion) to reduce tumor burden while preserving surrounding glandular tissue and function. Modalities discussed include focal laser ablation, high-intensity focused ultrasound (HIFU), cryoablation, radiofrequency ablation (RFA), photodynamic therapy, irreversible electroporation, and investigational magnetic nanoparticle approaches. The available evidence is heterogeneous, lacks prospective comparative trials, and is insufficient to demonstrate improved net health outcomes.

Definitions

Index lesion — definition

DefinitionThe largest cancerous lesion with the highest-grade tumor targeted by focal therapy.

Clinical rolePrimary target for focal ablation intended to reduce overall tumor burden while sparing uninvolved glandular parenchyma.

Alternative targetsFocal therapy may also target non-index lesions or other areas known to harbor cancer, but the index lesion is the principal lesion of concern.

Focal treatment — definition (ablation with preservation of uninvolved gland)

DefinitionA treatment approach that ablates cancerous lesions at high risk of progression while leaving uninvolved glandular parenchyma intact to preserve function.

GoalMinimize risk of early tumor progression and preserve erectile, urinary, and rectal function by reducing damage to surrounding structures (neurovascular bundles, external sphincter, bladder neck, rectum).

ModalitiesIncludes focal laser ablation, HIFU, cryoablation, radiofrequency ablation (RFA), photodynamic therapy, and irreversible electroporation; most use ultrasound guidance except focal laser ablation which uses MRI.

ScopeAblation is focused on identified lesion(s) rather than whole-gland treatment to minimize morbidity from radical therapies.